The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance

    Año de publicación: 2016

    The specific objectives were to evaluate the harms to benefits ratio of delamanid in combination with the currently recommended MDR-TB treatment regimen in children. Based on this evaluation, to develop recommendations on the use of delamanid as part of WHO-recommended longer MDR-TB treatment regimens, as appropriate, keeping in mind the attention to concerns relevant to the use of a new medicine for which Phase III clinical trial data are not yet available.

    Más Relacionados